Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

First Drug Regimen Shown to Prevent AML Relapse

TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released new clinical data that demonstrate a durable improvement in leukemia-free survival (LFS) over five years among Acute Myeloid Leukemia (AML) patients who receive post-consolidation immunotherapy with Ceplene(TM) (histamine dihydrochloride) in conjunction with low dose interleukin-2 (IL-2). These data were presented on December 9th at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Ceplene is EpiCept's registration stage product candidate for the remission, maintenance and prevention of relapse of patients with AML in first remission, and is currently under late stage review by the European Medicines Evaluation Agency (EMEA).

"These important findings add to the growing body of evidence demonstrating that the combination of Ceplene and low-dose IL-2 is the first drug regimen capable of prolonging leukemia-free survival and preventing relapse among AML patients in first remission," remarked Jack Talley, President and CEO of EpiCept. "While the Phase III study of Ceplene was powered to show a leukemia-free survival benefit over 36 months, these additional data provide confirmation of a lasting leukemia-free benefit for at least five years. We are continuing to work closely with regulators in Europe on our Marketing Authorization Application for Ceplene and remain on track to receive a final decision by the European Commission during the first half of 2008."

Mats L. Brune, MD, Medical Director of the Bone Marrow Transplant Program at the University of Goteborg delivered the findings in a poster presentation entitled, "Post-consolidation Immunotherapy with Histamine Dihydro
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... By Kathleen Doheny ... (HealthDay News) -- Birth control pills containing high doses ... the risk of breast cancer in women under 50, ... oral contraceptive formulations," explained lead researcher Elisabeth Beaber, a ... in Seattle. "Some of these formulations increase breast cancer ...
(Date:8/1/2014)... Roaming the high Alps more than 5,000 years ago, ... Man" no doubt had a very tough and active lifestyle. ... the Ice Man, nicknamed Otzi, from a very modern scourge: ... "hardening of the arteries," appears to be the same today ... finds. "Our ancestors going back thousands of years ...
(Date:8/1/2014)... The European gas chromatography systems report defines ... forecast of revenue. The gas chromatography systems market in Europe ... to grow to around $247.6 million by 2018, at a ... the TOC of the European gas chromatography systems market, to ... provides a glimpse of the segmentation of gas chromatography systems ...
(Date:8/1/2014)... to a new market research report of "Thermocouples and ... (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace & Defense) ... & Forecast to 2010 - 2020", published by MarketsandMarkets, ... Billion by 2020 at a CAGR of 3.70% and ... $238.17 Million by 2020 at a CAGR of 13.81% ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... the field of aging has chosen J. ... 2014 recipient of the Distinguished Career Contribution to ... annually to an individual whose theoretical contributions have ... or have yielded original and elegant research designs ...
Breaking Medicine News(10 mins):Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 2Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 3Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2
... VIEW, Calif., Nov. 20 Omnicell, Inc. (Nasdaq: OMCL ) a ... company will present at the 21st Annual Piper Jaffray Healthcare Conference ... , Omnicell Speakers: Randall A. Lipps, founder, chairman, president & ... Tuesday, December 1, 2009 , Time: 1:00 p.m. EST , ...
... , NEW YORK, Nov. 20 Today, ... announce the launch of a capsule gift giving collection offered exclusively ... is inspired by and designed for St. Jude,s Children,s Research Hospital,s ... program which encourages consumers to "give thanks for the healthy kids ...
... DEL REY, Calif., Nov. 20 Heritage Provider Network, and its ... November 6, 2009, Lakeside Medical Systems, Inc., as well as all ... of the HPN family. , "We first and foremost want to ... are dedicated to maintaining the high level of care they are ...
... ... the national healthcare network, to deliver multispecialty physicians for locum tenens (temporary substitute) ... ... Healthcare is pleased to announce its agreement with VHA Inc., the national healthcare ...
... , NEW ... new market research report is available in its ... Market Review , http://www.reportlinker.com/p0164325/Imaging-Agents---A-Worldwide-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... visualization of organs within the human body. With ...
... , Carrying and Lifting Tips to Keep you Injury-free this ... travelers have a saying - " Pack your bags, then take out ... bring much more than we need on our trips. Now, even ... are charging passengers a fee for checking luggage . However, ...
Cached Medicine News:Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 3Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 2Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 3Health News:VHA Names Jackson Healthcare as Preferred Physician Staffing Vendor 2Health News:VHA Names Jackson Healthcare as Preferred Physician Staffing Vendor 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 2Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 4Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 5Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 6Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 7Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 8Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 9Health News:This Thanksgiving, Lug your Luggage Safely 2Health News:This Thanksgiving, Lug your Luggage Safely 3
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek ... that it has initiated the development of its lead ... and that it has selected Quotient Clinical, The Translational ... (UK) to run its early development programs. ... Trial Application (CTA) by the end of the third ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
... SAN DIEGO, Jan. 31 TargeGen, Inc. ... multi-center Phase I/II clinical trial of,TG101348, an ... JAK2 in,patients with myeloproliferative diseases., (Logo: ... of JAK2 is implicated in the pathogenesis ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Cached Medicine Technology:TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: